Today on Drug Discovery & Development
U.S. should have enough COVID-19 vaccine by Q3 2021, CDC head tells Senate panel
AstraZeneca resumes COVID-19 vaccine trial
Drug Discovery and Development See More >
BioAscent spending £1M to boost drug discovery service offering
BioAscent (Newhouse, U.K.) recently announced that it will spend £1 million ($1.3 million) on new instrumentation and equipment. The investment is meant to further enhance the company’s offerings in integrated drug discovery and compound management. The new instrumentation will include a FLIPR Penta screening system and a Biacore 8k Surface Plasmon Resonance (SPR) system, as…
Genomics/Proteomics See More >
Illumina may buy back Grail
Illumina (NSDQ:ILMN) may acquire Grail for more than $8 billion — four years after it spun out the cancer detection startup. That’s according to a Bloomberg report out yesterday, which cited people familiar with the matter. Analysts told Bloomberg that the acquisition would put Illumina — a giant in the DNA sequencing space — in direct…
Infectious Disease See More >
AstraZeneca resumes COVID-19 vaccine trial
AstraZeneca (NYSE:AZN) has resumed its COVID-19 vaccine trial in the U.K. following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to proceed. The news of the trial resumption, announced Sept. 12, came six days after a voluntary pause so that an independent committee could review safety data surrounding a single event of…
Oncology See More >
Mission Bio completes $70M Series C for its tech to enable better cancer treatments
Mission Bio has secured $70 million in Series C financing to scale its single-cell multi-omics technology, according to the company. Novo Growth, the growth equity of Novo Holdings, led the round that included new investor Soleus Capital. Previous investors Mayfield, Cota, and Agilent also participated in the financing, which brings the company’s total funding to…
